## CL: Colgate-Palmolive Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 -4.5% below STRENGTH zone (4.0-10.0%); PEG 1.60 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.04)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Colgate-Palmolive (CL) Upgraded to Outperform, Target Price Rais**
- Source: GuruFocus | 20251209T200258 | Bullish | Relevance: 99%
-  RBC Capital Markets has upgraded Colgate-Palmolive (CL) to "Outperform" and raised its target price by 18% to $88, citing the company's consistent organic sales growth and effective management strategies despite global economic challenges. The report highlights Colgate-Palmolive's strong market position in household and personal care, robust international sales, and ownership of Hill's pet food. While noting a declining operating margin and high debt-to-equity ratio as warning signs, the analysis suggests a stable outlook with potential for growth, supported by a strong Altman Z-Score and positive analyst sentiment.

**2. Baird Financial Group Inc. Sells 15,457 Shares of Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251208T083629 | Neutral | Relevance: 99%
- Baird Financial Group Inc. reduced its stake in Colgate-Palmolive Company by 9.4% during the second quarter, selling 15,457 shares to own 149,272 shares valued at $13.57 million. Despite this, other institutional investors like Vanguard Group Inc. and Price T Rowe Associates Inc. MD increased their holdings significantly. The article also provides a financial overview of Colgate-Palmolive, including stock performance, earnings, dividends, and analyst ratings.

**3. Federated Hermes Inc. Has $42.44 Million Stake in Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251209T100812 | Neutral | Relevance: 98%
-  Federated Hermes Inc. decreased its stake in Colgate-Palmolive Company (NYSE:CL) by 22.2% during the second quarter, still holding 466,895 shares worth $42.44 million. Other institutional investors have adjusted their holdings, with 80.41% of the company's stock owned by institutional investors and hedge funds. Analyst ratings for Colgate-Palmolive currently lean towards a "Moderate Buy" with an average price target of $89.87.

**4. RBC’s Confidence in Colgate-Palmolive’s Margins and Cash Flow Might Change The Case For Investing In CL**
- Source: Simply Wall Street | 20251210T024611 | Bullish | Relevance: 98%
-  RBC Capital has upgraded Colgate-Palmolive to Outperform, citing strong revenue, pricing power, and high gross margins, alongside robust free cash flow generation. This upgrade reinforces the existing investment narrative that Colgate-Palmolive (CL) can convert brand strength and pricing power into steady cash flow. The company’s share repurchase program further highlights its strong cash generation, although risks remain from rising palm oil and packaging costs.

**5. RBC Capital upgrades Colgate-Palmolive stock to Outperform on favorable setup**
- Source: Investing.com | 20251209T085103 | Bullish | Relevance: 98%
-  RBC Capital has upgraded Colgate-Palmolive (NYSE:CL) from Sector Perform to Outperform, maintaining an $88.00 price target, signaling significant upside potential as the stock is considered undervalued. The upgrade follows pressure on shares due to slowing global category growth, and the firm believes expectations have been appropriately lowered, setting up a favorable return to long-term growth. Colgate-Palmolive recently reported increased net sales and EPS for Q2 2025, confirming guidance for low single-digit EPS growth for the year.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | RBC Capital | $88 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | RBC Capital | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 12 ($0.07M) |
| Sells | 23 ($1.66M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.2%)
- Blackrock Inc.: 8.6% (+0.5%)
- State Street Corpora: 6.0% (+0.2%)
- Price (T.Rowe) Assoc: 4.0% (-11.5%)
- Geode Capital Manage: 2.7% (+4.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.6% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 10.7% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.60 elevated, pricing in significant growth expectations. Forward P/E 20.0x stretched relative to 5% growth. Quality metrics strong (ROE 294%, ROA 15%). Balance sheet: $1.1B free cash flow. Insider selling cluster ($1.7M in 90 days), potential headwind. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $62.2B |
| Beta | 0.29 |
| 52W Range | $74.55 - $100.18 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.60 |
| Forward P/E | 20.0 |
| Current P/E | 21.0 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.8% to -4.5% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.5pp (needs >4.0% for momentum thesis). Below SMA200 (0.89x), long-term trend not supportive. RSI neutral at 43.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.46% (CS: 22) | Weak |
| RSI_14 | 43.2 | Neutral |
| MACD Histogram | -0.32 | Bearish |
| vs SMA20 | 0.977x | Below |
| vs SMA50 | 0.984x | Below |
| vs SMA200 | 0.893x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $76.98
- **Stop Loss:** $74.04 (3.8% risk)
- **Target:** $79.92 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 170
- **Position Value:** $13,086.60
- **Portfolio %:** 13.09%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-30 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.89 | $0.91 | +2.4% |
| 2025Q2 | $0.89 | $0.92 | +2.8% |
| 2025Q1 | $0.86 | $0.91 | +6.1% |
| 2024Q4 | $0.89 | $0.91 | +2.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*